332 related articles for article (PubMed ID: 12725708)
21. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors.
Ceriello A; Del Prato S; Bue-Valleskey J; Beattie S; Gates J; de la Peña A; Malone J
J Diabetes Complications; 2007; 21(1):20-7. PubMed ID: 17189870
[TBL] [Abstract][Full Text] [Related]
22. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
[TBL] [Abstract][Full Text] [Related]
23. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs.
Lankisch MR; Ferlinz KC; Leahy JL; Scherbaum WA;
Diabetes Obes Metab; 2008 Dec; 10(12):1178-85. PubMed ID: 19040645
[TBL] [Abstract][Full Text] [Related]
24. Review of phase 2 studies utilizing the AIR particle technology in the delivery of human insulin inhalation powder versus subcutaneous regular or lispro insulin in subjects with type 1 or type 2 diabetes.
Ellis SL; Gemperline KA; Garg SK
Diabetes Technol Ther; 2007 Jun; 9 Suppl 1():S48-56. PubMed ID: 17563304
[TBL] [Abstract][Full Text] [Related]
25. Clinical outcomes with insulin lispro compared with human regular insulin: a meta-analysis.
Davey P; Grainger D; MacMillan J; Rajan N; Aristides M; Gliksman M
Clin Ther; 1997; 19(4):656-74. PubMed ID: 9377611
[TBL] [Abstract][Full Text] [Related]
26. Insulin therapy in type 2 diabetes.
Mudaliar S; Edelman SV
Endocrinol Metab Clin North Am; 2001 Dec; 30(4):935-82. PubMed ID: 11727406
[TBL] [Abstract][Full Text] [Related]
27. Rapid-acting insulin analogues in Basal-bolus regimens in type 1 diabetes mellitus.
Garg S; Ampudia-Blasco FJ; Pfohl M
Endocr Pract; 2010; 16(3):486-505. PubMed ID: 20150026
[TBL] [Abstract][Full Text] [Related]
28. Subcutaneous insulin: pharmacokinetic variability and glycemic variability.
Guerci B; Sauvanet JP
Diabetes Metab; 2005 Sep; 31(4 Pt 2):4S7-4S24. PubMed ID: 16389894
[TBL] [Abstract][Full Text] [Related]
29. New aspects of insulin therapy in type 1 and type 2 diabetes.
Dills DG
Curr Diab Rep; 2001 Oct; 1(2):112-8. PubMed ID: 12643106
[TBL] [Abstract][Full Text] [Related]
30. Combining insulins for optimal blood glucose control in type I and 2 diabetes: focus on insulin glulisine.
Ulrich H; Snyder B; Garg SK
Vasc Health Risk Manag; 2007; 3(3):245-54. PubMed ID: 17703632
[TBL] [Abstract][Full Text] [Related]
31. Challenges in optimal metabolic control of diabetes.
Liebl A
Diabetes Metab Res Rev; 2002; 18 Suppl 3():S36-41. PubMed ID: 12324984
[TBL] [Abstract][Full Text] [Related]
32. Improvement of glycemic control and quality-of-life by insulin lispro therapy: Assessing benefits by ITR-QOL questionnaires.
Ishii H; Anderson JH; Yamamura A; Takeuchi M; Ikeda I
Diabetes Res Clin Pract; 2008 Aug; 81(2):169-78. PubMed ID: 18495289
[TBL] [Abstract][Full Text] [Related]
33. A review of types 1 and 2 diabetes mellitus and their treatment with insulin.
Salsali A; Nathan M
Am J Ther; 2006; 13(4):349-61. PubMed ID: 16858171
[TBL] [Abstract][Full Text] [Related]
34. Newer insulin analogs: advances in basal insulin replacement.
Zinman B
Diabetes Obes Metab; 2013 Mar; 15 Suppl 1():6-10. PubMed ID: 23448197
[TBL] [Abstract][Full Text] [Related]
35. Insulin therapy for type 2 diabetes: premixed or basal-prandial?
Halbron M; Jacqueminet S; Sachon C; Bosquet F; Hartemann-Heurtier A; Grimaldi A
Diabetes Metab; 2007 Sep; 33(4):316-20. PubMed ID: 17466560
[TBL] [Abstract][Full Text] [Related]
36. Defining the role of basal and prandial insulin for optimal glycemic control.
Horton ES
J Am Coll Cardiol; 2009 Feb; 53(5 Suppl):S21-7. PubMed ID: 19179213
[TBL] [Abstract][Full Text] [Related]
37. Prandial Insulins: A Person-Centered Choice.
Attri B; Nagendra L; Dutta D; Shetty S; Shaikh S; Kalra S; Bhattacharya S
Curr Diab Rep; 2024 Jun; 24(6):131-145. PubMed ID: 38568467
[TBL] [Abstract][Full Text] [Related]
38. Treatment of the patient with diabetes: importance of maintaining target HbA(1c) levels.
Davidson JA
Curr Med Res Opin; 2004 Dec; 20(12):1919-27. PubMed ID: 15701210
[TBL] [Abstract][Full Text] [Related]
39. Impact of improving postprandial glycemic control with intensifying insulin therapy in type 2 diabetes.
Yacoub T
Postgrad Med; 2017 Nov; 129(8):791-800. PubMed ID: 29032696
[TBL] [Abstract][Full Text] [Related]
40. Insulin lispro is as effective as regular insulin in optimising metabolic control and preserving beta-cell function at onset of type 1 diabetes mellitus.
Recasens M; Aguilera E; Morínigo R; Casamitjana R; Nicoletti F; Gomis R; Conget I
Diabetes Res Clin Pract; 2003 Jun; 60(3):153-9. PubMed ID: 12757987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
